Jazz Pharmaceuticals Inc

Type: Company
Name: Jazz Pharmaceuticals Inc
First reported 7 hours ago - Updated 7 hours ago - 1 reports

Benzinga's Top Initiations

Analysts at Longbow Research initiated coverage on shares of Norwegian Cruise Line Holdings (NASDAQ: NCLH) with a “buy” rating. The target price for Norwegian Cruise Line is set to $38. Norwegian Cruise Line's shares closed at $29.81 yesterday.Jefferies ... [Published Benzinga.com - 7 hours ago]
First reported Apr 16 2014 - Updated 16 hours ago - 1 reports

CBRE to sell Burlington House

CBRE have been instructed by Paul McCann, Grant Thornton, Receiver of Glasbay Limited (In Receivership) to bring the property to the market Burlington House in the heart of Dublin 4 by Private Treaty. The sale represents a significant office development ... [Published CoStar Uk - Apr 16 2014]
First reported Apr 16 2014 - Updated 17 hours ago - 1 reports

Biopharma fair has 750 jobs going

Wednesday, April 16 11:21:04The National Institute for Bioprocessing Research and Training (NIBRT) today held its inaugural 'Careers in Biopharma' job fair with 15 companies, recruiting for over 750 open positions.The jobs come from across the biopharma ... [Published Ireland Business World - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Block beside Burlo down from €105m to €25m

One of the best-located office redevelopment opportunities in Dublin city comes on the market today with the planned sale of a key site beside the former Burlington Hotel .The site has full planning permission for a high density office block with a net ... [Published Irish Times - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Jazz Pharmaceuticals (JAZZ) Showing Bearish Technicals

After closing Monday at $128.25, Jazz Pharmaceuticals Inc. (JAZZ) presents an attractive opportunity to get a 6.34% return in just 67 days, which is an annualized return of 34.53% (for comparison purposes only). To enter this trade, sell one Jun. '14 ... [Published MarketIntelligenceCenter.com - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Positive News And Stocks At Bargain Prices

SummaryNow that the market is well off its highs, this week offers a great opportunity to grab bargains and watch for positive surprises in well-priced stocks. Positive economic news trumped the beating of the war drums. Plenty of additional economic ... [Published Seeking Alpha - Apr 15 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Pharma Stocks on our Radar -- Research on AVANIR Pharma, Zoetis, Salix Pharma, and Jazz Pharma

/PRNewswire/ --The trading session on Wednesday, April 09, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,437.18, up 1.11% and the NASDAQ Composite closed at 4,183.90, up 1.72%. The S&P 500 finished the session 1.09% ... [Published Nasdaq - Apr 10 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

Jazz Pharmaceuticals And Gentium Announce European Commercial Launch Of First Approved Life-Saving Treatment For Severe Hepatic Veno-Occlusive Disease

By a News Reporter-Staff News Editor at Clinical Trials Week -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Gentium S.p.A ., a Jazz Pharmaceuticals company, announced the commencement of the European commercial launch of Defitelio®(?) (defibrotide), the ... [Published 4 Traders - Apr 10 2014]
First reported Apr 07 2014 - Updated Apr 08 2014 - 1 reports

Jazz Pharmaceuticals Shares Down 14.3% Since SmarTrend's Sell Call (JAZZ)

SmarTrend identified a Downtrend for Jazz Pharmaceuticals (NASDAQ:JAZZ) on March 3rd, 2014 at $150.30. In approximately 1 month, Jazz Pharmaceuticals has returned 14.26% as of today's recent price of $128.87. ... [Published Individual.com - Apr 07 2014]
First reported Apr 01 2014 - Updated Apr 02 2014 - 2 reports

ALLIANCE PHARMA : Appointment of Non-Executive Director

Release date- 01042014 - Alliance Pharma plc ('Alliance' or the 'Company'), the specialty pharmaceutical company, is pleased to announce the appointment of David Cook as an independent Non-executive Director of the Company, effective 1 April 2014 .David ... [Published 4 Traders - Apr 02 2014]
First reported Mar 31 2014 - Updated Apr 01 2014 - 6 reports

EU roll out begins for Jazz' Defitelio

Jazz Pharmaceuticals has kicked off the European rollout of its rare liver disease drug Defitelio (defibrotide), with launches this week in Germany and Austria.Defitelio is the first licensed product for the treatment of (severe VOD or sVOD) in patients ... [Published Pharma Times - Mar 31 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 2 reports

ARIA Stock Gets Big Boost From JAZZ Buyout Rumors

Ariad Pharmaceuticals ‘ ( ARIA ) is getting a boost from buyout rumors, sending ARIA stock up nearly 7% in Friday trading.Online business cites are buzzing on speculation that Jazz Pharmaceuticals ( JAZZ ) is considering a buyout upward of $20/share — ... [Published InvestorPlace.com - Mar 28 2014]

Quotes

Dr Reg Shaw, CEO of NIBRT said, "The Irish biopharma industry continues to go from strength-to-strength including recent expansion announcements from companies such as Regeneron, Biomarin, Alexion, Jazz Pharmaceuticals. NIBRT is delighted to support this growth by holding a Careers in Biopharma event at our facility to match industry with appropriately qualified people."
..." He urged "lower tax rates for businesses that create jobs here at home."
Zoetis Inc. "s stock finished the session 0.31% lower at $29.06. A total of 3.63 million shares were traded, which is below its three months average volume of 4.97 million shares. The stock fluctuated between $28.77 and $29.22 during the session. The company's shares traded at a PE ratio of 21.15. Zoetis Inc." s stock has fallen by 0.89% in the previous three trading sessions, 4.97% in the last one month and 11.10% on YTD basis...
...reported), but the secondary endpoint of OS was not met, although there was a strong trend in favor of talimogene laherparepvec (p=0.051). "We remain encouraged that the study met its primary endpoint of achieving durable responses in patients with metastatic melanoma" said Sean E Harper, M D , Executive Vice President of ResearchResearch and Development at Amgen. The full analyst notes on Amgen Inc...

More Content

All (140) | News (108) | Reports (0) | Blogs (18) | Audio/Video (0) | Fact Sheets (0) | Press Releases (14)
sort by: Date | Relevance
Top Analysts Action: WTFC, NFLX, BAC, SCTY, AA [Published BayStreet.ca - 3 hours ago]
Benzinga's Top Initiations [Published Benzinga.com - 7 hours ago]
Jazz Pharmaceuticals (JAZZ) Trading Near $127.1... [Published MarketIntelligenceCenter.com - 8 hours ago]
Canaccord Genuity Reiterates Buy Rating for Jaz... [Published American Banking News - Forex - 8 hours ago]
Insider Selling: Jeffrey K. Tobias Sells 3,000 ... [Published American Banking News - Forex - 17 hours ago]
CBRE to sell Burlington House [Published CoStar Uk - Apr 16 2014]
NIBRT hosts biopharma job fair advertising 750 ... [Published Department of Enterprise - Apr 16 2014]
Momentum ETF Changes for Q2 [Published Yahoo! Finance - Apr 16 2014]
Block beside Burlo down from €105m to €25m [Published Irish Times - Apr 16 2014]
First Careers in Biopharma fair seeks to match ... [Published Business & Leadership - Apr 16 2014]
Potential Jazz Pharmaceuticals (JAZZ) Trade Has... [Published MarketIntelligenceCenter.com - Apr 16 2014]
Biopharma fair has 750 jobs going [Published Ireland Business World - Apr 16 2014]
Jazz Pharmaceuticals (JAZZ) Showing Bearish Tec... [Published MarketIntelligenceCenter.com - Apr 15 2014]
Editorial: If Walgreen moves its HQ, blame Wash... [Published Chicago Tribune - Apr 15 2014]
Positive News And Stocks At Bargain Prices [Published Seeking Alpha - Apr 15 2014]
Jazz Pharmaceuticals Has Returned 11.5% Since S... [Published Comtex SmarTrend - Apr 14 2014]
Jazz Pharmaceuticals Has Returned 11.5% Since S... [Published Individual.com - Apr 14 2014]
Jazz Pharmaceuticals (JAZZ) Showing Resistance ... [Published MarketIntelligenceCenter.com - Apr 14 2014]
Fast And Furious Selloff Provides Important Mar... [Published Investing.com - Apr 14 2014]
The boardroom fixtures [Published Irish Independent - Apr 13 2014]
Jazz Pharmaceuticals plc CEO Unloads $615,900 i... [Published American Banking News - Apr 11 2014]
Pharma Stocks on our Radar -- Research on AVANI... [Published Nasdaq - Apr 10 2014]
Pharma Stocks on our Radar -- Research on AVANI... [Published Financial Services - Apr 10 2014]
Acquisitions, Trial Study Results, Drug Trend R... [Published Finwin - Apr 10 2014]
Acquisitions, Trial Study Results, Drug Trend R... [Published ADVFN India - Apr 10 2014]
Sleep Health, Sleep Apnea and Sleep Disorders: ... [Published Press News.org - Apr 10 2014]
Jazz Pharmaceuticals And Gentium Announce Europ... [Published 4 Traders - Apr 10 2014]
Jazz Pharma: Risk 7% Downside, 34% Upside To Fa... [Published BioPortfolio - Apr 09 2014]
Jazz and Gentium launch veno-occlusive disease ... [Published Individual.com - Apr 09 2014]
Shares of Pozen Rank the Highest in Terms of Re... [Published Comtex SmarTrend - Apr 09 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Jazz Pharmaceuticals (JAZZ) Trading Near $127.1... [Published MarketIntelligenceCenter.com - 8 hours ago]
The patented option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center are highlighting two trades on Jazz Pharmaceuticals Inc. (JAZZ) today after it closed at $136.10 on Wednesday. For more conservative ...
Potential Jazz Pharmaceuticals (JAZZ) Trade Has... [Published MarketIntelligenceCenter.com - Apr 16 2014]
After Tuesday’s trading in Jazz Pharmaceuticals Inc. (JAZZ) MarketIntelligenceCenter.com's option trade-picking algorithms uncovered a trade that offers a 7.79% or 43.06% (for comparison purposes only), while providing 7.87% downside protection. The trade ...
Jazz Pharmaceuticals (JAZZ) Showing Bearish Tec... [Published MarketIntelligenceCenter.com - Apr 15 2014]
After closing Monday at $128.25, Jazz Pharmaceuticals Inc. (JAZZ) presents an attractive opportunity to get a 6.34% return in just 67 days, which is an annualized return of 34.53% (for comparison purposes only). To enter this trade, sell one Jun. '14 ...
Jazz Pharmaceuticals (JAZZ) Showing Resistance ... [Published MarketIntelligenceCenter.com - Apr 14 2014]
Jazz Pharmaceuticals Inc. (JAZZ) is a good candidate for a covered call at the $125.00 level. The Jun. '14 call at that price should fetch a credit of about $12.10, which means the entire position has a net debit of about $116.51. This trade has 7.71% ...
Jazz Pharmaceuticals And Gentium Announce Europ... [Published PR Newswire: Health - Mar 31 2014]
DUBLIN and VILLA GUARDIA, Italy, March 31, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Gentium S.p.A., a Jazz Pharmaceuticals company, today announced the commencement of the European commercial launch of Defitelio®▼ (defibrotide), ...
1 2 3 4

Press Releases

sort by: Date | Relevance
Pharma Stocks on our Radar -- Research on AVANI... [Published Financial Services - Apr 10 2014]
Meda enters partnership for Elestrin in the US ... [Published GlobeNewswire: Acquisitions News - Mar 14 2014]
Gentium S.p.A. Announces Decision to Voluntaril... [Published GlobeNewswire: Advertising News - Mar 05 2014]
Jazz Pharmaceuticals plc Completes Tender Offer... [Published Financial Services - Feb 21 2014]
Jazz Pharmaceuticals plc Announces Minimum Tend... [Published Financial Services - Jan 23 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.